Pharma major Lupin announced the launch of its Clobetasol Propionate Cream USP 0.05%, having received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin’s Clobetasol Propionate Cream USP 0.05% is the generic equivalent of Fougera Pharmaceuticals Inc.'s Temovate Cream, 0.05%. It is a super-high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Clobetasol Propionate Cream USP 0.05% had annual sales of approximately USD 108.6 million in the US (IQVIA MAT June 2018).
Shares of the company gained Rs 19.4, or 2.23%, to settle at Rs 889.20. The total volume of shares traded was 273,797 at the BSE (Tuesday).